The companies have not published the trial data but said in a news release that the experimental treatment extended the time ...
Aug 19 (Reuters) - Moderna and Merck said on Wednesday that a personalized mRNA cancer vaccine reduced the risk of recurrence ...
Merck and Moderna say the experimental treatment extended the time before skin cancer returned in patients at high risk.
By Michael Erman and Julie Steenhuysen Aug 19 (Reuters) - Moderna and Merck said on Wednesday that a personalized mRNA cancer ...
The combination regimen significantly extended the time patients lived without their melanoma returning, compared with ...
Merck and Moderna say their new vaccine can block the return of one of the deadliest cancers. These personalized mRNA ...
A cancer vaccine developed by Merck and Moderna treating patients with melanoma showed positive and promising late-stage ...
A personalized vaccine developed by Moderna Inc. and Merck & Co. helped reduce the recurrence of melanoma in a large, ...
Drug company stocks soared following news that Moderna and Merck’s experimental mRNA-based cancer vaccine succeeded in a late ...
A late-stage trial that combined a messenger ribonucleic acid (mRNA) shot jointly developed by Moderna (MRNA +130.82%) and ...
Combining a vaccine and immunotherapy approach could open new ways to treat cancer.
A personalized vaccine developed by Moderna Inc. and Merck & Co. helped reduce the recurrence of melanoma in a large, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results